Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • ChrysCapital in talks...

    ChrysCapital in talks to buy stake in Dr Agarwal's Health Care: Report

    Written by Ruby Khatun Khatun Published On 2018-08-21T13:38:24+05:30  |  Updated On 21 Aug 2018 1:38 PM IST
    ChrysCapital in talks to buy stake in Dr Agarwals Health Care: Report

    Mumbai: ChrysCapital is in advanced talks with Dr Agarwal’s Health Care Ltd to acquire a minority stake for about Rs 200-250 crore, according to a recent media report.


    Currently, Dr Agarwal’s Health Care owns about 71.75 percent in the listed entity and has 75 eye care centers, out of which 61 are in India and 14 in Cambodia, Ghana, Mauritius, Mozambique, Nigeria, and Rwanda.


    Dr Agarwal’s Eye Hospital Ltd will use the funds to expand the eye care chain in new markets. Investment bank Veda Corporate Advisors has been signed up by Dr Agarwal's promoters.

    A person knowing about the matter told ET, “ChrysCapital has signed an exclusivity agreement and the discussions moving to an advanced stage.”


    In 2016, ADV Partners, a Hong-Kong based private equity fund had invested $45 million in the company which makes Evolvence India Life Sciences Fund to exit that had acquired a minority stake for Rs 60 crore in 2012 in the company.


    Dr Agarwal’s raised Rs 160 crore through a structured debt arrangement from Edelweiss Special Opportunities Fund II in July last year.


    Adil Agarwal, the CEO of Dr Agarwal’s Eye Hospital Ltd told ET, “We are in the process of raising growth capital to meet our expansion plans and talks are on with several private equity players.”


    It has been reported that the firm is planning to enter new markets in south India and open 50 centers in next two-three years.

    Medical Dialogues had reported in April this year that Mankind Pharma had agreed to sell its 10 percent stake to ChrysCapital and its global sponsors for about $350 million, or Rs 2,280 crore.


    Read also: BIG DEAL: ChrysCapital to buy 10 percent stake in Mankind for Rs 2,280 crore


    In March 2018, ChrysCapital had made a surprise bid and snatches the deal from global rivals Advent International and Carlyle Group.


    Read also: ChrysCapital makes Surprise bid for Mankind Pharma stake

    Adil AgarwalADV PartnersChrysCapitaldiscussionsDr Agarwal's Health CareDr Agarwal’s Eye Hospital LtdDr Agarwal’s Health Care LtdEvolvence India Life Sciences Fundexclusivity agreementMankind Pharmaminority stakestake
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok